Detail akcie Medexus Pharma Rg online

Business Summary: Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of hematology-oncology and allergy, dermatology, and rheumatology. It operates through two product portfolios: Medexus Pharma Canada and Medexus Pharma. Its lead products are IXINITY (US), GRAFAPEX (US), Trecondyv (Canada), Rupall (Canada), Rasuvo (US), Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Financial Summary: BRIEF: For the six months ended 30 September 2025, Medexus Pharmaceuticals Inc revenues decreased 8% to $49.4M. Net income decreased 90% to $201K. Revenues reflect Canada (Country) segment decrease of 41% to $13.4M. Net income also reflects Employee benefit expense increase of 26% to $12.9M (expense), Selling and administrative expenses - Ba increase of 14% to $7M (expense).